Drug Profile

Astressin - RELIEF THERAPEUTICS Holding

Latest Information Update: 18 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator mondoBIOTECH
Developer RELIEF THERAPEUTICS Holding
Class Antihormones
Mechanism of Action Angiogenesis inhibitors; Corticotropin-releasing hormone inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

18 Sep 2023 Discontinued - Preclinical for Vascular disorders in Switzerland (unspecified route) (RELIEF THERAPEUTICS pipeline, September 2023)
28 Apr 2018 No recent reports of development identified for preclinical development in Vascular-disorders in Switzerland
19 Sep 2016 Astressin is available for licensing as of 19 Sep 2016. http://www.relieftherapeutics.com/further-opportunities/

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com